Boston Scientific ($BSX) revealed more details about its leadless pacemaker program, as it seeks to join Medtronic ($MDT) and St. Jude Medical ($STJ) in that market (which does not yet exist in the U.S., where the devices are still being investigated). The company revealed its plans to enter the market during its recent investor day. Boston Scientific senior vice president Dr. Ken Stein added additional color at the Heart Rhythm Society meeting in Boston, saying: "While on the one hand, we see that leadless pacing may be interesting for a small niche of patients who just need single-chamber pacemakers, actually to us the bigger opportunity is pairing it with the S-ICD, so that if you have patients who need defibrillators but who also need pacing, or also need anti-tachycardia pacing, now they've got a full, comprehensive option for anti-tachycardia pacing or back up VVI pacing." More